|
1
|
Ferrara N and Kerbel RS: Angiogenesis as a
therapeutic target. Nature. 438:967–974. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ellis LM and Hicklin DJ: VEGF-targeted
therapy: Mechanisms of anti-tumour activity. Nat Rev Cancer.
8:579–591. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hurwitz HI, Tebbutt NC, Kabbinavar F,
Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D and Tabernero J:
Efficacy and safety of bevacizumab in metastatic colorectal cancer:
Pooled analysis from seven randomized controlled trials.
Oncologist. 18:1004–1012. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Klement G, Baruchel S, Rak J, Man S, Clark
K, Hicklin DJ, Bohlen P and Kerbel RS: Continuous low-dose therapy
with vinblastine and VEGF receptor-2 antibody induces sustained
tumor regression without overt toxicity. J Clin Invest.
105:R15–R24. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Klement G, Huang P, Mayer B, Green SK, Man
S, Bohlen P, Hicklin D and Kerbel RS: Differences in therapeutic
indexes of combination metronomic chemotherapy and an anti-VEGFR-2
antibody in multidrug-resistant human breast cancer xenografts.
Clin Cancer Res. 8:221–232. 2002.PubMed/NCBI
|
|
6
|
Bennouna J, Sastre J, Arnold D, Österlund
P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C,
et al ML18147 Study Investigators: Continuation of bevacizumab
after first progression in metastatic colorectal cancer (ML18147):
A randomised phase 3 trial. Lancet Oncol. 14:29–37. 2013.
View Article : Google Scholar
|
|
7
|
von Minckwitz G, Puglisi F, Cortes J,
Vrdoljak E, Marschner N, Zielinski C, Villanueva C, Romieu G, Lang
I, Ciruelos E, et al: Bevacizumab plus chemotherapy versus
chemotherapy alone as second-line treatment for patients with
HER2-negative locally recurrent or metastatic breast cancer after
first-line treatment with bevacizumab plus chemotherapy (TANIA): An
open-label, randomised phase 3 trial. Lancet Oncol. 15:1269–1278.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jubb AM, Oates AJ, Holden S and Koeppen H:
Predicting benefit from anti-angiogenic agents in malignancy. Nat
Rev Cancer. 6:626–635. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shi H, Jiang J, Ji J, Shi M, Cai Q, Chen
X, Yu Y, Liu B, Zhu Z and Zhang J: Anti-angiogenesis participates
in antitumor effects of metronomic capecitabine on colon cancer.
Cancer Lett. 349:128–135. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan F, Shi H, Ji J, Cai Q, Chen X, Yu Y,
Liu B, Zhu Z and Zhang J: Capecitabine metronomic chemotherapy
inhibits the proliferation of gastric cancer cells through
anti-angiogenesis. Oncol Rep. 33:1753–1762. 2015.PubMed/NCBI
|
|
11
|
Yanagisawa M, Yorozu K, Kurasawa M, Nakano
K, Furugaki K, Yamashita Y, Mori K and Fujimoto-Ouchi K:
Bevacizumab improves the delivery and efficacy of paclitaxel.
Anticancer Drugs. 21:687–694. 2010.PubMed/NCBI
|
|
12
|
Kopetz S, Hoff PM, Morris JS, Wolff RA,
Eng C, Glover KY, Adinin R, Overman MJ, Valero V, Wen S, et al:
Phase II trial of infusional fluorouracil, irinotecan, and
bevacizumab for metastatic colorectal cancer: Efficacy and
circulating angiogenic biomarkers associated with therapeutic
resistance. J Clin Oncol. 28:453–459. 2010. View Article : Google Scholar :
|
|
13
|
Fujimoto-Ouchi K, Sekiguchi F, Yamamoto K,
Shirane M, Yamashita Y and Mori K: Preclinical study of prolonged
administration of trastuzumab as combination therapy after disease
progression during trastuzumab monotherapy. Cancer Chemother
Pharmacol. 66:269–276. 2010. View Article : Google Scholar
|
|
14
|
Iwai T, Moriya Y, Shirane M,
Fujimoto-Ouchi K and Mori K: Continuous inhibition of epidermal
growth factor receptor phosphorylation by erlotinib enhances
antitumor activity of chemotherapy in erlotinib-resistant tumor
xenografts. Oncol Rep. 27:923–928. 2012.PubMed/NCBI
|
|
15
|
Maniati E and Hagemann T: IL-17 mediates
resistance to anti-VEGF therapy. Nat Med. 19:1092–1094. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Casanovas O, Hicklin DJ, Bergers G and
Hanahan D: Drug resistance by evasion of antiangiogenic targeting
of VEGF signaling in late-stage pancreatic islet tumors. Cancer
Cell. 8:299–309. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Erber R, Thurnher A, Katsen AD, Groth G,
Kerger H, Hammes HP, Menger MD, Ullrich A and Vajkoczy P: Combined
inhibition of VEGF and PDGF signaling enforces tumor vessel
regression by interfering with pericyte-mediated endothelial cell
survival mechanisms. FASEB J. 18:338–340. 2004.
|
|
18
|
Crawford Y, Kasman I, Yu L, Zhong C, Wu X,
Modrusan Z, Kaminker J and Ferrara N: PDGF-C mediates the
angiogenic and tumorigenic properties of fibroblasts associated
with tumors refractory to anti-VEGF treatment. Cancer Cell.
15:21–34. 2009. View Article : Google Scholar
|
|
19
|
Bergers G and Hanahan D: Modes of
resistance to anti-angiogenic therapy. Nat Rev Cancer. 8:592–603.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yamashita-Kashima Y, Fujimoto-Ouchi K,
Yorozu K, Kurasawa M, Yanagisawa M, Yasuno H and Mori K: Biomarkers
for antitumor activity of bevacizumab in gastric cancer models. BMC
Cancer. 12:372012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Waugh DJ and Wilson C: The interleukin-8
pathway in cancer. Clin Cancer Res. 14:6735–6741. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li D, Xie K, Ding G, Li J, Chen K, Li H,
Qian J, Jiang C and Fang J: Tumor resistance to anti-VEGF therapy
through up-regulation of VEGF-C expression. Cancer Lett. 346:45–52.
2014. View Article : Google Scholar
|
|
23
|
Griffioen AW and Thijssen VL: Galectins in
tumor angiogenesis. Ann Transl Med. 2:902014.PubMed/NCBI
|
|
24
|
Endo K, Kohnoe S, Tsujita E, Watanabe A,
Nakashima H, Baba H and Maehara Y: Galectin-3 expression is a
potent prognostic marker in colorectal cancer. Anticancer Res.
25:3117–3121. 2005.PubMed/NCBI
|
|
25
|
Croci DO, Cerliani JP, Dalotto-Moreno T,
Méndez-Huergo SP, Mascanfroni ID, Dergan-Dylon S, Toscano MA,
Caramelo JJ, García-Vallejo JJ, Ouyang J, et al:
Glycosylation-dependent lectin-receptor interactions preserve
angiogenesis in anti-VEGF refractory tumors. Cell. 156:744–758.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Markowska AI, Liu FT and Panjwani N:
Galectin-3 is an important mediator of VEGF- and bFGF-mediated
angiogenic response. J Exp Med. 207:1981–1993. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Markowska AI, Jefferies KC and Panjwani N:
Galectin-3 protein modulates cell surface expression and activation
of vascular endothelial growth factor receptor 2 in human
endothelial cells. J Biol Chem. 286:29913–29921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
D'Haene N, Sauvage S, Maris C, Adanja I,
Le Mercier M, Decaestecker C, Baum L and Salmon I: VEGFR1 and
VEGFR2 involvement in extracellular galectin-1- and
galectin-3-induced angiogenesis. PLoS One. 8:e670292013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Partridge EA, Le Roy C, Di Guglielmo GM,
Pawling J, Cheung P, Granovsky M, Nabi IR, Wrana JL and Dennis JW:
Regulation of cytokine receptors by Golgi N-glycan processing and
endocytosis. Science. 306:120–124. 2004. View Article : Google Scholar : PubMed/NCBI
|
